Pliant Therapeutics Initiates Phase 2a Trial Enrollment of Bexotegrast for Primary Sclerosing Cholangitis Treatment

Pliant Therapeutics, a biopharmaceutical company focused on treating fibrosis, has begun Phase 2a enrollment for its bexotegrast to treat primary sclerosing cholangitis (PSC). The trial follows a positive safety review by an independent Data Safety Monitoring Board. Bexotegrast is a small molecule inhibitor for αvβ6 and αvβ1 integrins and has been administered to over 600 participants with no severe or serious side effects reported.

Publish Date: 13-03-2023 Source: Pliant Therapeutics

Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by bile duct inflammation and fibrosis and strongly associated with inflammatory bowel disease (IBD). The degree of involvement of the biliary system can vary. Most patients with primary sclerosing cholangitis have underlying inflammatory bowel diseases, such as ulcerative colitis or Crohn’s disease. Patients diagnosed with primary sclerosing cholangitis (PSC) are more likely to have ulcerative colitis compared to Crohn’s disease (85% versus 15%), with approximately 2.5-7.5% of all ulcerative colitis patients having PSC. In more than 80% of patients, the strictures (narrowing of the bile ducts) are present in both the intrahepatic (within the liver) and extrahepatic (outside the liver) ducts. However, about 10% of these patients have intrahepatic strictures only, while less than 5% will have only extrahepatic strictures. The majority of people with PSC have no symptoms. These patients are typically diagnosed when abnormal biochemical tests of liver function are detected during routine blood testing. Despite the presence of advanced disease, patients may remain asymptomatic for many years.

The incidence of Primary sclerosing cholangitis ranges between 0.4 to 1.30 cases per 100,000 people per year.

However, the current Primary Sclerosing Cholangitis (PSC) treatment market share, market uptake, and attribute analysis concerning the most potential emerging therapies (Cenicriviroc, Cilofexor, etc..) has been provided under the market outlook section of the study covering 8 MM countries; The United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, several pharmaceutical products are being approved and under different phases of development for the Primary Sclerosing Cholangitis treatment. The key companies in the advanced development stage are Tobira Therapeutics, Inc., Gilead Sciences, etc..

Based on solid domain and business knowledge, Thelansis Knowledge Partners has published the market outlook forecast report on Primary Sclerosing Cholangitis (PSC) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2021 to 2032.

About Thelansis:

Thelansis specializes in pharmaceutical market outlook and market forecast reports. We published reports across the therapeutic area, including rare / ultra-rare and mainstream indications. Over the period, we have built a robust repository of 6,000+ Bio-pharma reports that cover Epidemiology studies and Market forecasting based on the KOL opinions.

Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the primary focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.